Complications With Femring

Serious Femring Side Effects

Some side effects of Femring (or of estrogen medications in general) are rare but are serious enough to mention. These serious but rare side effects include:
 
Because of the potentially serious nature of these side effects, there are a few symptoms that you should watch out for and report to your healthcare provider if they occur. These include but are not limited to:
 
  • Signs of a blood clot in the leg, such as:
 
    • Pain in the calf
    • Leg cramps
    • Leg or foot swelling
 
  • Signs of a blood clot in the lung, such as:
 
    • Shortness of breath
    • Sharp chest pain
    • Coughing up blood
 
 
    • Vision or speech changes
    • Weakness or numbness in an arm or leg
    • Severe headache
 
  • Signs of liver damage, such as:
 
    • Yellowing of the whites of the eyes or skin (jaundice)
    • Dark urine
    • Upper-right abdominal pain (stomach pain)
 
  • Migraines (or changes in your migraines, if you have had them before)
  • Breast lumps
  • Chest pain or heaviness, which may be signs of a heart attack
  • Sudden loss of vision or vision changes, which can be a sign of a blood clot in the eye
  • Heavy vaginal bleeding or unexpected vaginal bleeding
  • Signs of toxic shock syndrome, such as:
     
    • A fever
    • Nausea and vomiting
    • Muscle pain
    • Dizziness and faintness
    • Sunburn-like rash on the face and body

 

  • Signs of an allergic reaction, including:
 
    • An unexplained rash
    • Hives
    • Itching
    • Unexplained swelling
    • Wheezing
    • Difficulty breathing or swallowing.
 
4 Reasons BPH Affects Your Libido

Femring Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.